Iron Removal In vivo Study (IRIS)
Infections and inflammation of the eyes are becoming increasingly prevalent problems for patients
with chronic diseases or for people who use implanted eye lenses. Serious ocular infectious and
inflammatory disease can lead to significant visual disability and requires aggressive treatment
intervention to mitigate disease pathology and prevent vision loss. Preliminary work suggests that ironchelating
agents developed by Chelation Partners Incorporated can effectively control microbes and
inflammation. These excipients can enhance the power of antibiotics, especially in clinically resistant
infections, dampen inflammation and reduce the need for harsh preservatives. Studies will be designed
to: (i) evaluate the safety of the excipients, (ii) determine the ability of these agents to control
inflammatory response in the eye (iii) examine the ability of these agents to limit eye infections or their
ability to enhance the anti-microbial activity of antibiotics. Results of these studies will be valuable in
assessing the safety and efficacy of these iron-chelating agents in vivo (in animals) prior to their TOBECONTINUED
View Full Project DescriptionChristian Lehmann;Melanie Kelly
Chelation Partners Inc
Life Sciences
Manufacturing
Dalhousie University
Accelerate
